Volume 14 Supplement 1
6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications
Meeting abstracts
Edited by John C Burnett Jr, Franz Hofmann, Kazuwa Nakao, Harald HHW Schmidt and Johannes-Peter Stasch
Publication of this supplement has been fully funded by Bayer Pharma AG. Johannes-Peter Stasch is an employee of Bayer Pharma AG, Wuppertal, Germany. He holds many patents on sGC stimulators and sGC activators. John C Burnett Jr is the chairman of the advisory board for Nile Therapeutics and is a Co-Founder and the Chief Scientific Officer for Zumbro Discovery. Mayo Clinic has licensed CD-NP to Nile Therapeutics and MANP to Zumbro Discovery. The other Supplement Editors declare that they have no competing interests.
6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications. Go to conference site.
Erfurt, Germany28-30 June 2013
Page 1 of 3
-
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O1
-
Increased nitrosative/oxidative stress lowers myocardial protein kinase G activity in heart failure with preserved ejection fraction
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O2 -
Abstract not submitted for publication
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O3 -
Lessons from tissue-specific KO of CNP/GC-B system - everlasting challenge to clinical application
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O4 -
What have genome-wide association studies taught us about cGMP and blood pressure regulation?
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O5 -
Genetic variants in guanylyl cyclase and phoshodiesterase affecting coronary disease risk
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O6 -
Genetic variants of ANP and cardiometabolic protection: from populations to novel therapeutics
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O7 -
Genetic modifiers of hypertension in sGC-deficient mice
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O8 -
Pulmonary vascular adaptation to high-altitude living
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O9 -
MicroRNA miR-425 is a negative regulator of atrial natriuretic peptide
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O10 -
cGMP kinase: past, presence and future
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O11 -
Conformational changes involved in sGC activation
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O12 -
A twenty year journey to understand how ATP activates guanylyl cyclase A and B
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O13 -
Soluble guanylate cyclase crystal clear: 1stcrystal structure of the wild-type human heterodimeric sGC catalytic domains and implications for activity
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O14 -
Crystal structures of human soluble guanylate cyclase catalytic domains: promiscuity of the dimer interface and a potential allosteric site
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O15 -
Structures of human PKG reveal cGMP-selectived activation mechanisms
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O16 -
Targeting native and apo-sGC
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O17 -
Mechanisms driving heme insertion into apo-sGC during its maturation in cells
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O18 -
Redox signalling by protein kinase G Iα in cardiovascular physiology and pathology
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O19 -
New mechanisms of normoxic and hypoxic cGMP signalling mediated by the nitrite anion
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O20 -
Thiol-redox proteins interact with soluble guanylyl cyclase and modulate its activity
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O21 -
Chronic beta-adrenergic blockade prevents volume overload-induced re-localization and oxidation of soluble guanylyl cyclase
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O22 -
Elementary Ca2+signals through endothelial TRPV4 channels regulate vascular function
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O23 -
Natriuretic peptides and fat metabolism
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O24 -
Role of cGMP in fat and metabolism
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O25 -
Non-genomic thyroid hormone signaling through NO/cGMP/PKGII
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O26 -
cGMP-Prkg1 signaling PDE5 inhibition shelter cochlear hair cells and hearing function
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O27 -
GUCY2C at the intersection of obesity and colorectal cancer
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O28 -
Cell type-specific knock out models to unravel NO/cGMP signaling in smooth muscle
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O29 -
Interstitial cells of Cajal link excitatory and nitrergic inhibitory neurotransmission with slow-wave activity in the intestine
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O30 -
cGMP-dependent kinase 2, Na+/H+ regulatory factor 2, and Na+/H+ exchanger isoform 3 assemble within lipid rafts in murine small intestinal brush border membrane
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O31 -
NO-H2S interactions involve cGMP
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O32 -
67-kDa laminin receptor and cGMP induced cancer-selective apoptosis
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O33 -
A novel physiological significance of natriuretic peptides in cancer metastasis
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O34 -
Dual actions of ANP on endothelial permeability
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O35 -
Pseudomonas aeruginosaExoY, a cyclic GMP- and cyclic UMP-generating nucleotidyl cyclase
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O36 -
Nitric oxide regulated cyclic di-GMP signaling
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O37 -
Differential effects of PDE5 inhibitors on cardiac dysfunction in the MDX ouse model of Duchenne muscular dystrophy
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):O38 -
Neutral endopeptidase inhibitors SOL-1 and candoxatril counteract kidney fibrosis by reducing myofibroblast formation in mouse UUO model
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P1 -
Hydroxyurea reduces leukocyte interactions with the vessel wall in a haemolytic mouse model via a possible NO/cGMP-mediated effect
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P2 -
Effect of nitrite treatment on endothelial nitric oxide synthase in human left ventricle biopsy
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P3 -
A possible crosstalk between cGMP pathway and Activin receptor-like kinase 7 (Alk7) in adipocytes
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P4 -
Pharmacokinetic interaction of ketoconazole, clarithromycin, and midazolam with riociguat
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P5 -
Effects of omeprazole and AlOH/MgOH on riociguat absorption
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P6 -
Absorption behavior of riociguat: bioavailability, food effects, and dose-proportionality
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P7 -
Role of NO-sensitive guanylyl cyclase in angiogenesis and arteriogenesis
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P8 -
NO-cGMP signalling and cancer therapy
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P9 -
Identification of protein kinase G I alpha interacting proteins as potential targets to prevent cardiac remodeling
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P10 -
G-protein signaling modulator 1 is a modifier of sGC-dependent vascular response
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P11 -
Identification and quantitation of 2´,3´-cGMP in murine tissues
Citation: BMC Pharmacology and Toxicology 2013 14(Suppl 1):P12
Annual Journal Metrics
-
2022 Citation Impact
2.9 - 2-year Impact Factor
2.9 - 5-year Impact Factor
0.932 - SNIP (Source Normalized Impact per Paper)
0.603 - SJR (SCImago Journal Rank)2022 Speed
22 days submission to first editorial decision for all manuscripts (Median)
198 days submission to accept (Median)2022 Usage
642,939 downloads
1,154 Altmetric mentions
Peer-review Terminology
-
The following summary describes the peer review process for this journal:
Identity transparency: Single anonymized
Reviewer interacts with: Editor
Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication